AGLARIS LIMITED
ActiveKey figures
Like most small UK companies, AGLARIS LIMITED does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.
Ratios
2025Sector comparison
SIC 72110Where the company stands among the 3,991 active companies whose first SIC code is 72110 (Research and experimental development on biotechnology).
- BRACCO HORIZONS LIMITED£526.1m
- TAURX THERAPEUTICS MANAGEMENT LTD.£470.3m
- LABCORP EARLY DEVELOPMENT LABORATORIES LIMITED£317m
- JAZZ PHARMACEUTICALS RESEARCH UK LIMITED£289.2m
- GENOME RESEARCH LIMITED£273.7m
- MODERNA BIOTECH UK LIMITED£236.5m
- CURIA (SCOTLAND) LIMITED£183m
- ASTEX THERAPEUTICS LIMITED£163.6m
- HORIZON DISCOVERY GROUP LIMITED£159.6m
- AMGEN LIMITED£134.4m
Positions are approximate. Figures come from each company's latest accounts; money and employee figures are compared only with companies that filed accounts in pounds for a period ending in the last two and a half years and are not dormant, so those groups are smaller than 3,991. The line on each bar marks the median.
Summary: AGLARIS LIMITED
What kind of company is it?
AGLARIS LIMITED is a private limited company registered with Companies House under company number 09111674. It was incorporated on 2 Jul 2014. Its status is active. The registered office is in London (W1W). Its nature of business (SIC 2007) is research and experimental development on biotechnology (72110).
How is the company doing financially?
The latest accounts in the database are for 2025 (period ending 31 Dec 2025); the company files small company accounts (filleted). Net assets were £4,449,307, down 17.1% on the previous year. Cash at bank and in hand was £203,409. The company had an average of 1 employee. Figures are available for 6 financial years (2020–2025).
How does it compare with similar companies?
Compared with 3,991 active companies whose first SIC code is 72110: By net assets it ranks higher than 91% of them (median £20,978). By total assets it ranks higher than 90% of them (median £125,654). By cash it ranks higher than 58% of them (median £101,976). By number of employees it is around the median of them (1). It is older than 80% of them (median age 5.4 years).
Has it received government grants?
It is recorded as the recipient of one central government grant worth £724.5k, from Department for Business, Energy and Industrial Strategy.
Who runs and controls the company?
The company has 7 current directors. One person with significant control is registered. 1 of 1 registered charges are outstanding.
When are its next filings due?
The next accounts are due by 30 Sep 2027. The next confirmation statement is due by 30 Oct 2027.
Filed accounts2020–2025
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Cash at bank and in hand | 177,067 | 27,446 | 1,802 | 479,669 | 203,409 |
| Total assets | 5,426,464 | 5,810,718 | 5,955,152 | 6,631,807 | 6,559,517 |
| Total liabilities | — | — | — | — | — |
| Net assets / total equity | 4,479,769 | 3,981,899 | 3,559,839 | 5,364,659 | 4,449,307 |
| Average number of employees | 8 | 8 | 5 | 2 | 1 |
A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.
Government grants
1 grantAGLARIS LIMITED is recorded as the recipient of 1 central government grant, worth £724.5k.
- Development of transduction process in cell culture platformDepartment for Business, Energy and Industrial Strategy · £724,476 · UKRI - Innovate UK - Scheme 22/23
From the Government Grants Register published by the Cabinet Office (financial years 2016/17 onwards, Open Government Licence v3.0). It covers grants from central government departments and their agencies where the register states the recipient's company number and the recipient name matches this company; grants from local authorities, lottery distributors and devolved governments are not included.
History
30 events- Financial year 2025 endedAccounts: net assets £4.4m, 1 employee
- Financial year 2024 endedAccounts: net assets £5.4m, 2 employees
- 3-GUTINVER, S.L. appointedDirector (corporate)
- Financial year 2023 endedAccounts: net assets £3.6m, 5 employees
- Steven John DOCKSEY resignedDirector
- Financial year 2022 endedAccounts: net assets £4m, 8 employees
- Financial year 2021 endedAccounts: net assets £4.5m, 8 employees
- Financial year 2020 endedAccounts: net assets £1.6m, 9 employees
Earlier events (22)
- Pablo CABELLO ALBENDEA resignedDirector
- Joaquin VELASCO appointedDirector
- Crb Bio Ii, Fcr registered as a person with significant control
- Francisco CANAL VEGA resignedDirector
- Steven John DOCKSEY appointedDirector
- Dr David Horna Tomás ceased to be a person with significant control
- Dr Miquel Costa Ferrando ceased to be a person with significant control
- Manuel Fuertes DOMINGUEZ resignedDirector
- Jose Antonio CASTILLO GONZALEZ appointedDirector
- BIO CELL GLOBAL INVESTMENTS S.L appointedDirector (corporate)
- Francisco CANAL VEGA appointedDirector
- Dr David Horna Tomás registered as a person with significant control
- Dr Miquel Costa Ferrando registered as a person with significant control
- Angel José SANTOS IGLESIAS appointedDirector
- Pablo CABELLO ALBENDEA appointedDirector
- FLEXIBLE DIRECTORS LIMITED resignedSecretary (corporate)
- Miquel COSTA FERRANDO appointedSecretary
- Manuel Fuertes DOMINGUEZ appointedDirector
- Miquel COSTA FERRANDO appointedDirector
- David HORNA TOMÁS appointedDirector
- FLEXIBLE DIRECTORS LIMITED appointedSecretary (corporate)
- Company incorporatedPrivate limited company
Dates as recorded at Companies House: incorporation, name changes, officer appointments and resignations, current and former persons with significant control, and the end of each financial year with figures in the database.